Answer-shaped evidence
Start with a direct, cited answer, then inspect the exact trials, literature metadata, regulatory records, source dates, and visible limitations behind it.
Coverage-gated collection
U.S. label record.↗ The cited DailyMed label identifies Exenatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
U.S. label record.↗ The cited DailyMed label identifies Abaloparatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
U.S. label record.↗ The cited DailyMed label identifies Semaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
U.S. label record.↗ The cited DailyMed label identifies Glucagon and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
U.S. label record.↗ The cited DailyMed label identifies Liraglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
U.S. label record.↗ The cited DailyMed label identifies Tirzepatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
Investigational.↗ ClinicalTrials.gov lists an Amgen bioavailability study as completed, updated July 21, 2026.↗
U.S. label record.↗ The cited DailyMed label identifies Octreotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
U.S. label record.↗ The cited DailyMed label identifies Teriparatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
U.S. label record.↗ The cited DailyMed label identifies Dulaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
FDA compounding safety review.↗↗ FDA presented MOTS-c briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.↗↗
Investigational.↗ ClinicalTrials.gov lists a Boehringer Ingelheim study as active, not recruiting, updated July 22, 2026.↗
Investigational.↗ ClinicalTrials.gov lists a Roche-sponsored combination study as not yet recruiting, updated July 7, 2026.↗
Investigational.↗ ClinicalTrials.gov lists an Eli Lilly study as active, not recruiting, with a registry update posted July 20, 2026.↗
U.S. label record.↗ The cited DailyMed label identifies Leuprolide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
U.S. label record.↗ The cited DailyMed label identifies Setmelanotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
U.S. label record.↗ The cited DailyMed label identifies Vosoritide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
Not an FDA-approved drug.↗ FDA presented BPC-157 briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding and FDA's final determination remains pending; the cited trial registration also does not establish safety or effectiveness.↗↗↗
Investigational.↗ ClinicalTrials.gov lists a Novo Nordisk pediatric study as recruiting, updated July 17, 2026.↗
Investigational.↗ ClinicalTrials.gov lists a West China Hospital study as not yet recruiting, updated July 21, 2026.↗
U.S. label record.↗ The cited DailyMed label identifies Ziconotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
U.S. label record.↗ The cited DailyMed label identifies Linaclotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
U.S. label record.↗ The cited DailyMed label identifies Tesamorelin and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
Investigational.↗ ClinicalTrials.gov lists Altimmune's IMPACT study as completed, last updated May 18, 2026.↗
FDA compounding-list review for non-injectable routes.↗ FDA lists GHK-Cu, except injectable routes, in Category 1 for bulk substances under evaluation. That listing does not establish FDA approval, safety, or effectiveness.↗
U.S. label record.↗ The cited DailyMed label identifies Lixisenatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
U.S. label record.↗ The cited DailyMed label identifies Afamelanotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
Investigational.↗ ClinicalTrials.gov lists the 4TAZPower study as recruiting, updated July 13, 2026.↗
FDA compounding safety review; final determination pending.↗↗ FDA's emideltide briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.↗↗
FDA compounding safety review; final determination pending.↗↗ FDA's Epitalon briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.↗↗
FDA compounding safety review; final determination pending.↗↗ FDA's KPV briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.↗↗
FDA compounding safety review; final determination pending.↗↗ FDA's Semax briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.↗↗
FDA compounding safety review; final determination pending.↗↗ FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.↗↗↗
U.S. label record.↗ The cited DailyMed label identifies Plecanatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
U.S. label record.↗ The cited DailyMed label identifies Bremelanotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
U.S. label record.↗ The cited DailyMed label identifies Pramlintide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
U.S. label record.↗ The cited DailyMed label identifies Insulin glargine-aldy and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
U.S. label record.↗ The cited DailyMed label identifies Lanreotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
Unapproved new drug in cited enforcement record.↗ FDA's compounding-risk page describes immunogenicity and characterization concerns. A separate Justice Department release names Ipamorelin among unapproved new drugs distributed by the cited pharmacy.↗↗
Investigational.↗ ClinicalTrials.gov lists a Novo Nordisk oral amycretin study as completed, last updated March 5, 2025.↗
Unapproved new drug in cited enforcement record.↗ FDA's compounding-risk page describes immunogenicity, impurity, and adverse-event concerns. A separate Justice Department release names CJC 1295 among unapproved new drugs distributed by the cited pharmacy.↗↗
Exact-label registry coverage
Selected by reproducible collection coverage, not medical importance. Each brief keeps exact registry labels, connected profile context, source chronology, recent collection changes, and unanswered gaps distinct.
36 exact-label ClinicalTrials.gov records across 10 registry-update years, connected to 12 peptide profiles.
18 exact-label ClinicalTrials.gov records across 9 registry-update years, connected to 1 peptide profile.
11 exact-label ClinicalTrials.gov records across 4 registry-update years, connected to 6 peptide profiles.
10 exact-label ClinicalTrials.gov records across 6 registry-update years, connected to 8 peptide profiles.
6 exact-label ClinicalTrials.gov records across 4 registry-update years, connected to 2 peptide profiles.
5 exact-label ClinicalTrials.gov records across 3 registry-update years, connected to 3 peptide profiles.
4 exact-label ClinicalTrials.gov records across 4 registry-update years, connected to 2 peptide profiles.
4 exact-label ClinicalTrials.gov records across 3 registry-update years, connected to 2 peptide profiles.
3 exact-label ClinicalTrials.gov records across 3 registry-update years, connected to 2 peptide profiles.
3 exact-label ClinicalTrials.gov records across 3 registry-update years, connected to 1 peptide profile.
Continue exploring